Rademikibart

DB18995InvestigationalProtein Based Therapies

Rademikibart is under investigation in clinical trial NCT04773678 (Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation).

Mechanism: Pharmacologically active on Interleukin-4 receptor subunit alpha
Curator reviewed
Code names: CBP-201

Resolves to

Compound

UNIINWV8DWU7QMCAS2648260-80-2

Targets

P24394IL4R

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rademikibart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account